Digital Health Localization Services

Digital health localization is the multilingual adaptation of healthcare apps, platforms, connected devices, digital therapeutics and AI-enabled healthcare tools. It typically includes UI strings, onboarding flows, notifications, microcopy, patient-facing instructions, clinical workflow text, in-app help, support articles, websites, app-store content, eIFUs, IFUs and regulatory documentation. The goal is accurate, complete and source-faithful localization aligned to your approved product content, supported by qualified linguists, healthcare terminology control, in-context review and traceable workflows that match the regulatory, clinical and usability implications of each content type and user group.

Healthcare app localization is typically managed by Product Managers, Digital Health Managers and Software Localization Managers inside digital health companies, medical software vendors, medical device manufacturers with companion apps, healthcare SaaS providers, telehealth platforms and digital therapeutics companies. Internal regulatory affairs, clinical, UX, AI governance and quality teams often participate in review steps. Localization supports product expansion into new markets, multilingual user experiences, patient-facing clarity, clinician adoption and the multilingual documentation that may need to accompany regulated healthcare products in each target country.

eHealth translation covers multilingual content for electronic health products and services, including patient portals, remote monitoring tools, telehealth platforms, healthcare SaaS interfaces, online clinical workflows and patient communication tools. It typically includes UI strings, patient messages, clinical content, help articles, regulatory documentation and supporting websites. eHealth translation focuses on accurate, consistent multilingual content aligned to the approved source, but it does not replace product, clinical, regulatory, medical, UX, AI governance or legal review by your internal teams, who remain responsible for final content decisions in each target market.

Digital therapeutics translation is the localization of digital therapeutics products, including therapeutic content, behavioural prompts, patient instructions, onboarding journeys, clinical workflows, program materials and supporting documentation. Because digital therapeutics often combine clinical evidence with software experiences, translation needs to handle medical clarity, user-facing tone and regulatory wording consistently. Digital therapeutics translation supports multilingual product availability but does not replace clinical validation, software validation, regulatory approval, AI performance assessment or final content approval, which remain with your clinical, regulatory, product and AI governance teams responsible for the product in each market.

No. The objective of every workflow is accurate, complete and source-faithful localization. What changes is the workflow used to manage the risk of not achieving that objective, the review depth, the cost and the turnaround. Lower-risk workflows may be appropriate for internal drafts, administrative help content, repeated UI strings, training support content or low-impact updates when internal controls support that decision. They are different processes for managing localization risk, not lower accuracy requirements. Higher-risk content such as patient instructions, clinical workflows, safety warnings, IFUs and regulatory documentation typically follows more robust workflows with independent revision.

No. Digital health localization helps you produce accurate, traceable multilingual content aligned to your approved source, but it does not guarantee regulatory approval, medical device classification, software validation, AI system performance, clinical validation, usability validation, authority acceptance, app-store approval, patient understanding, safe use, market access or business outcomes. Product strategy, regulatory submissions, clinical decisions, software validation, AI governance and final content approval remain with your internal product, clinical, regulatory, UX, AI governance, quality and legal teams. AbroadLink acts as a specialised language partner supporting your processes, not replacing them.

AI can be used in a controlled way for suitable digital health content, but it should not be used as an uncontrolled, generic translation source for regulated healthcare material. Through aiHubLink, AbroadLink uses customised generative AI as a pre-translation step based on your terminology and legacy translations, always followed by qualified human review and validation by healthcare software linguists. For medical software UI, digital therapeutics content, patient-facing instructions, clinical workflows, safety warnings, eIFUs, regulatory documentation and AI-enabled healthcare outputs, AI is positioned only as a controlled support option with documented human review.

CertLink is AbroadLink's portal for accessing translation certificates linked to your projects. Each certificate is signed and includes the project code, languages, content covered, linguists involved and, where relevant, information about controlled AI use during pre-translation. For digital health companies, CertLink provides a centralised, searchable place to retrieve evidence of localization work across releases, which can support internal release records, regulatory reviews, audits and authority questions. It complements, but does not replace, your internal product, regulatory, clinical, AI governance and quality records, which remain under your responsibility.